PURPOSE: To retrospectively analyze patient characteristics, treatment, and treatment outcome of pediatric patients with hematologic diseases treated with total body irradiation (TBI) between 1978 and 2006. PATIENTS AND METHODS: 32 pediatric patients were referred to the Department of Radiation-Oncology at the University of Zurich for TBI. Records of regular follow-up of 28 patients were available for review. Patient characteristics as well as treatment outcome regarding local control and overall survival were assessed. A total of 18 patients suffered from acute lymphoblastic leukemia (ALL), 5 from acute and 2 from chronic myelogenous leukemia, 1 from non-Hodgkin lymphoma, and 2 from anaplastic anemia. The cohort consisted of 15 patients referred after first remission and 13 patients with relapsed leukemia. Mean follow-up was 34 months (2-196 months) with 15 patients alive at the time of last follow-up. Eight patients died of recurrent disease, 1 of graft vs. host reaction, 2 of sepsis, and 2 patients died of a secondary malignancy. RESULTS: The 5-year overall survival rate (OS) was 60%. Overall survival was significantly inferior in patients treated after relapse compared to those treated for newly diagnosed leukemia (24% versus 74%; p=0.004). At the time of last follow-up, 11 patients survived for more than 36 months following TBI. Late effects (RTOG ≥ 3) were pneumonitis in 1 patient, chronic bronchitis in 1 patient, cardiomyopathy in 2 patients, severe cataractogenesis in 1 patient (48 months after TBI with 10 Gy in a single dose) and secondary malignancies in 2 patients (36 and 190 months after TBI). Growth disturbances were observed in all patients treated prepubertally. In 2 patients with identical twins treated at ages 2 and 7, a loss of 8% in final height of the treated twin was observed. CONCLUSION: As severe late sequelae after TBI, we observed 2 secondary malignancies in 11 patients who survived in excess of 36 months. However, long-term morbidity is moderate following treatment with the fractionated TBI at the low-dose rate that was generally used here. Conditioning for bone marrow transplantation without radiation is an attractive option, but is not sufficiently effective to completely replace TBI for the most common pediatric indications.
PURPOSE: To retrospectively analyze patient characteristics, treatment, and treatment outcome of pediatric patients with hematologic diseases treated with total body irradiation (TBI) between 1978 and 2006. PATIENTS AND METHODS: 32 pediatric patients were referred to the Department of Radiation-Oncology at the University of Zurich for TBI. Records of regular follow-up of 28 patients were available for review. Patient characteristics as well as treatment outcome regarding local control and overall survival were assessed. A total of 18 patients suffered from acute lymphoblastic leukemia (ALL), 5 from acute and 2 from chronic myelogenous leukemia, 1 from non-Hodgkin lymphoma, and 2 from anaplastic anemia. The cohort consisted of 15 patients referred after first remission and 13 patients with relapsed leukemia. Mean follow-up was 34 months (2-196 months) with 15 patients alive at the time of last follow-up. Eight patients died of recurrent disease, 1 of graft vs. host reaction, 2 of sepsis, and 2 patients died of a secondary malignancy. RESULTS: The 5-year overall survival rate (OS) was 60%. Overall survival was significantly inferior in patients treated after relapse compared to those treated for newly diagnosed leukemia (24% versus 74%; p=0.004). At the time of last follow-up, 11 patients survived for more than 36 months following TBI. Late effects (RTOG ≥ 3) were pneumonitis in 1 patient, chronic bronchitis in 1 patient, cardiomyopathy in 2 patients, severe cataractogenesis in 1 patient (48 months after TBI with 10 Gy in a single dose) and secondary malignancies in 2 patients (36 and 190 months after TBI). Growth disturbances were observed in all patients treated prepubertally. In 2 patients with identical twins treated at ages 2 and 7, a loss of 8% in final height of the treated twin was observed. CONCLUSION: As severe late sequelae after TBI, we observed 2 secondary malignancies in 11 patients who survived in excess of 36 months. However, long-term morbidity is moderate following treatment with the fractionated TBI at the low-dose rate that was generally used here. Conditioning for bone marrow transplantation without radiation is an attractive option, but is not sufficiently effective to completely replace TBI for the most common pediatric indications.
Authors: E Granados; R de La Cámara; L Madero; M A Díaz; P Martín-Regueira; J L Steegmann; R Arranz; A Figuera; J M Fernández-Rañada Journal: Haematologica Date: 2000-10 Impact factor: 9.941
Authors: M Robin; P Guardiola; A Devergie; M Yeshurun; S Shapiro; H Esperou; P Ribaud; V Rocha; E Gluckman; G Socié Journal: Leukemia Date: 2005-09 Impact factor: 11.528
Authors: D Blaise; D Maraninchi; E Archimbaud; J Reiffers; A Devergie; J P Jouet; N Milpied; M Attal; M Michallet; N Ifrah Journal: Blood Date: 1992-05-15 Impact factor: 22.113
Authors: Smita Bhatia; Leslie L Robison; Liton Francisco; Andrea Carter; Yan Liu; Marcia Grant; K Scott Baker; Henry Fung; James G Gurney; Philip B McGlave; Auayporn Nademanee; Norma K C Ramsay; Anthony Stein; Daniel J Weisdorf; Stephen J Forman Journal: Blood Date: 2005-02-08 Impact factor: 22.113
Authors: Bipin N Savani; Aldemar Montero; Colin Wu; Nene Nlonda; Elizabeth Read; Cynthia Dunbar; Richard Childs; Scott Solomon; A John Barrett Journal: Biol Blood Marrow Transplant Date: 2005-03 Impact factor: 5.742
Authors: A Devergie; D Blaise; M Attal; J D Tigaud; J P Jouet; J P Vernant; P Bordigoni; N Ifrah; C Dauriac; J Y Cahn Journal: Blood Date: 1995-04-15 Impact factor: 22.113
Authors: N V N Madhusudhana Sresty; Deleep Gudipudi; A Krishnam Raju; T Anil Kumar; V R P Lakshmi; G Srikanth; M Narasimha Journal: Strahlenther Onkol Date: 2021-04-14 Impact factor: 3.621
Authors: Kathleen M Overholt; Satoru Otsuru; Timothy S Olson; Adam J Guess; Victoria M Velazquez; Laura Desbourdes; Massimo Dominici; Edwin M Horwitz Journal: Blood Adv Date: 2017-12-14
Authors: Carl J Johnston; Casey M Manning; Javier Rangel-Moreno; Troy D Randall; Eric Hernady; Jacob N Finkelstein; Jacqueline P Williams Journal: Radiat Res Date: 2012-03-15 Impact factor: 2.841